{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:02:08Z","timestamp":1784984528453,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01587-8","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:33:13Z","timestamp":1784982793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selinexor for myelofibrosis or a drug in search of a disease?"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"1587_CR1","doi-asserted-by":"publisher","first-page":"78883","DOI":"10.18632\/oncotarget.12428","volume":"7","author":"T Kashyap","year":"2016","unstructured":"Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, et al. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016;7:78883\u201395.","journal-title":"Oncotarget"},{"key":"1587_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/jha2.709","volume":"4","author":"CC Mo","year":"2023","unstructured":"Mo CC, Yee AJ, Midha S, Hartley-Brown MA, Nadeem O, O\u2019Donnell EK, et al. Selinexor: Targeting a novel pathway in multiple myeloma. EJHaem. 2023;4:792\u2013810.","journal-title":"EJHaem"},{"key":"1587_CR3","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","volume":"129","author":"J Kuruvilla","year":"2017","unstructured":"Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017;129:3175\u201383.","journal-title":"Blood"},{"key":"1587_CR4","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1158\/1078-0432.CCR-18-0959","volume":"25","author":"D Yan","year":"2019","unstructured":"Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, et al. Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis. Clin Cancer Res. 2019;25:2323\u201335.","journal-title":"Clin Cancer Res"},{"key":"1587_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100010","volume":"1","author":"M Metzger","year":"2024","unstructured":"Metzger M, Avigan ZM, Vachhani P, Waksal J, Mascarenhas J. A novel application of XPO1 inhibition for the treatment of myelofibrosis. Blood Neoplasia. 2024;1:100010.","journal-title":"Blood Neoplasia"},{"key":"1587_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801\u201321.","journal-title":"Am J Hematol"},{"key":"1587_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc. 2012;87:25\u201333.","journal-title":"Mayo Clin Proc"},{"key":"1587_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599\u2013610.","journal-title":"Mayo Clin Proc"},{"key":"1587_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00780-9","volume":"13","author":"N Gangat","year":"2023","unstructured":"Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, et al. Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood Cancer J. 2023;13:3.","journal-title":"Blood Cancer J"},{"key":"1587_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A Double-blind, Placebo-controlled trial of Ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"1587_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"1587_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1:643\u201351.","journal-title":"JAMA Oncol"},{"key":"1587_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, et al. Pacritinib vs best available therapy, including Ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4:652\u20139.","journal-title":"JAMA Oncol"},{"key":"1587_CR14","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: A Phase III randomized trial of Momelotinib versus Ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis. J Clin Oncol. 2017;35:3844\u201350.","journal-title":"J Clin Oncol"},{"key":"1587_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, et al. Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129:1823\u201330.","journal-title":"Blood"},{"key":"1587_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ajh.27658","volume":"100","author":"GG Loscocco","year":"2025","unstructured":"Loscocco GG, Guglielmelli P. Targeted therapies in myelofibrosis: present landscape, ongoing studies, and future perspectives. Am J Hematol. 2025;100:30\u201350.","journal-title":"Am J Hematol"},{"key":"1587_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ajh.27659","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Tefferi A. Emerging pathogenetic mechanisms and new drugs for anemia in myelofibrosis and myelodysplastic Syndromes. Am J Hematol. 2025;100:51\u201365.","journal-title":"Am J Hematol"},{"key":"1587_CR18","unstructured":"Harrison C CL, Ross D et al. Elritercept (KER-050) Demonstrated Potential To Treat Myelofibrosis And Mitigate Ruxolitinib-Associated Cytopenias In The Phase 2 RESTORE Trial. EHA Abstract S. 223. 2024."},{"key":"1587_CR19","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1182\/bloodadvances.2024012939","volume":"8","author":"AT Gerds","year":"2024","unstructured":"Gerds AT, Harrison C, Kiladjian J-J, Mesa R, Vannucchi AM, Komrokji R, et al. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv. 2024;8:4511\u201322.","journal-title":"Blood Adv"},{"key":"1587_CR20","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1200\/JCO.2026.44.16_suppl.6501","volume":"44","author":"N Gangat","year":"2026","unstructured":"Gangat N, Tefferi A, Bose P, Hexner EO, Michaelis LC, Gerds AT, et al. RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis. J Clin Oncol. 2026;44:6501.","journal-title":"J Clin Oncol"},{"key":"1587_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood-2021-153940","volume":"138","author":"SK Tantravahi","year":"2021","unstructured":"Tantravahi SK, Kim SJ, Sundar D, Patel AB, Pomicter AD, Boucher KM, et al. A Phase 2 study to evaluate the efficacy and safety of Selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors. Blood. 2021;138:143.","journal-title":"Blood"},{"key":"1587_CR22","doi-asserted-by":"crossref","unstructured":"Tantravahi SKEA, Patel AB, et al. Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK Inhibitors. Blood Cancer J. 2026. In Press","DOI":"10.1038\/s41408-026-01571-2"},{"key":"1587_CR23","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/bloodadvances.2025018706","volume":"10","author":"H Ali","year":"2026","unstructured":"Ali H, Mohan S, Kishtagari A, Prchal JT, Maher K, Chai Y, et al. Selinexor plus ruxolitinib in JAK inhibitor\u2013na\u00efve patients with myelofibrosis: a multicenter, open-label, phase 1 study. Blood Adv. 2026;10:3383\u201397.","journal-title":"Blood Adv"},{"key":"1587_CR24","unstructured":"Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, et al. Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Na\u00efve Myelofibrosis: Phase III SENTRY Trial. J Clin Oncol. 2026:Jco2601080."},{"key":"1587_CR25","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S2352-3026(24)00067-X","volume":"11","author":"G Barosi","year":"2024","unstructured":"Barosi G, Tefferi A, Gangat N, Szuber N, Rambaldi A, Odenike O, et al. Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024;11:e383\u2013e9.","journal-title":"Lancet Haematol"},{"key":"1587_CR26","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","volume":"31","author":"RK Rampal","year":"2025","unstructured":"Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, et al. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med. 2025;31:1531\u20138.","journal-title":"Nat Med"},{"key":"1587_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/blood-2023-173509","volume":"142","author":"N Pemmaraju","year":"2023","unstructured":"Pemmaraju N, Mead AJ, Somervaille TCP, McCloskey JK, Palandri F, Koschmieder S, et al. Transform-1: a randomized, double-blind, placebo-controlled, multicenter, International Phase 3 study of Navitoclax in combination with Ruxolitinib versus Ruxolitinib plus placebo in patients with untreated myelofibrosis. Blood. 2023;142:620.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01587-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01587-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01587-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:33:14Z","timestamp":1784982794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01587-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1587"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01587-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NG has served on the Advisory Board for Agios and DISC Medicine.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"122"}}